MEI Pharma (NASDAQ: MEIP) announced new pre-clinical data showing mitochondria-specific effects of the Company's investigational drug candidate ME-344 in cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE